Learning Where to Look: Anatomical Grounding and Guided Attention for Cardiac MRI Vision-Language Models
Organizations: Rutgers University, NJ, USA · United Imaging Intelligence, Boston, MA, USA · University of Texas Southwestern Medical Center, TX, USA · Duke University, NC, USA
Abstract
Cardiac magnetic resonance imaging (CMR) enables assessment of cardiac anatomy, ventricular function, and myocardial tissue characteristics. Clinicians interpret these images by identifying cardiac structures and focusing on the regions relevant to each clinical question, motivating anatomically guided vision-language models (VLMs). Yet CMR-specific supervision for anatomical localisation and clinical question answering remains limited. To address this gap, we investigate fine-grained CMR visual question answering through anatomical grounding and guided attention. We construct 128,915 anatomical-grounding and 42,799 clinical QA pairs across short-axis cine, late gadolinium enhancement, and long-axis cine. These datasets support anatomical recognition, localisation, and clinical assessment without requiring paired reports for individual training images. To help the model learn where to look, we introduce Cardiac Anatomy-Routed Attention (CARA), which selects predicted anatomical priors according to the question and guides decoder attention with learned task-specific strengths. Combining anatomical grounding pretraining with CARA yields our model, CARA-VL. Experiments demonstrate CARA-VL's strengths in clinical assessment and regional localisation across CMR imaging settings, with promising generalization to an external clinical cohort. Together, our data and method provide a practical framework for studying and advancing cardiac visual understanding in VLMs. We will release the QA data derived from public datasets upon publication.
Figures & tables
| (a) SAX cine | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Model | Hyper. | LV size | RV size | EF | GRS | GCS | Avg. | Reg. hyper. | Reg. motion |
| General medical VLMs | |||||||||
| LLaVA-Med-7B | 50.0 / 9.9 | 50.0 / 24.3 | 50.0 / 42.4 | 47.5 / 39.9 | 50.0 / 41.0 | 50.0 / 38.8 | 49.6 / 32.7 | 9.2 | 31.2 |
| MedGemma-4B-it | 56.6 / 55.7 | 60.7 / 46.0 | 36.7 / 35.5 | 50.0 / 27.8 | 50.0 / 23.4 | 51.1 / 39.4 | 50.9 / 38.0 | 9.2 | 31.9 |
| Huatuo-Vision | 50.0 / 47.1 | 50.0 / 24.3 | 50.0 / 20.9 | 50.0 / 27.8 | 52.1 / 35.5 | 59.5 / 59.5 | 51.9 / 35.9 | 0.9 | 24.1 |
| Lingshu-7B | 50.0 / 47.1 | 44.4 / 27.6 | 50.8 / 22.7 | 50.0 / 27.8 | 39.2 / 39.5 | 45.7 / 43.5 | 46.7 / 34.7 | 3.2 | 16.9 |
| Model | Reference | Hyper. | LV size | RV size | EF | GRS | GCS | Avg. | Reg. hyper. | Reg. motion |
|---|---|---|---|---|---|---|---|---|---|---|
| General medical VLMs | ||||||||||
| LLaVA-Med-7B | Rule-based | 50.0 / 13.3 | 50.6 / 16.2 | 50.0 / 49.4 | 49.0 / 47.3 | 50.0 / 47.6 | 50.0 / 48.5 | 49.9 / 37.0 | 7.2 | 10.5 |
| Report-based | 50.0 / 23.0 | 50.4 / 41.2 | 50.0 / 40.4 | 49.6 / 49.4 | 50.0 / 42.8 | 50.0 / 43.0 | 50.0 / 40.0 | 32.2 | 28.9 | |
| MedGemma-4B-it | Rule-based | 58.3 / 48.6 | 56.1 / 43.0 | 52.2 / 48.9 | 49.8 / 27.6 | 48.9 / 13.3 | 46.5 / 36.1 | 51.9 / 36.2 | 7.2 | 12.7 |
| Report-based | 52.9 / 50.7 | 55.9 / 55.7 | 51.3 / 48.8 | 50.1 / 21.8 | 48.0 / 23.5 | 47.4 / 44.0 | 50.9 / 40.7 | 32.2 | 39.0 | |
| Huatuo-Vision | Rule-based | 49.5 / 48.9 | 50.0 / 11.1 | 50.0 / 2.3 | 50.0 / 24.1 | 47.3 / 19.3 | 55.8 / 46.7 | 50.4 / 25.4 | 3.3 | 9.2 |
| Model | Stage-1 | CARA | BA | Macro- |
|---|---|---|---|---|
| CARA-VL (Ours) | 90.7 | 90.0 | ||
| w/o Stage-1 | 88.4 | 87.9 | ||
| w/o CARA | 86.8 | 86.5 | ||
| w/o Stage-1 and CARA | 86.2 | 86.0 |
Appendix figures & tables16 assets
Supplementary material from the paper’s appendix.
Appendix
| Domain | Task and answer categories | Frames | Measurement and labelling rule |
| SAX | Hypertrophy: present / absent | ED | Present if any AHA segment has ED wall thickness ; source-labelled normal cases are assigned negative. |
| Regional hypertrophy: segment list | ED | Segments with ED wall thickness ; six segments at basal and mid-ventricular levels, four at the apical level. | |
| LV size: normal / mild / moderate / severe dilation | ED+ES | Patient-level LV EDV: , , , and , respectively. | |
| EF: normal / mild / moderate / severe reduction | ED+ES | Whole-stack area-ratio EF: , , , and , respectively. | |
| RV size: dilated / normal | ED+ES | Dilated if RV EDV and RV/LV EDV ratio ; single-criterion positives require visual confirmation. Normal if both are below threshold; unconfirmed candidates are excluded. | |
| GRS surrogate: normal / reduced | ED+ES | Mean systolic wall thickening: normal, reduced; exclude . |
| Domain | Source | Mask source | Stage-1 | Stage-2 train | Held out |
| Public datasets | |||||
| SAX | ACDC | Expert | 100 (8,845) | 89 (1,803) | 50 |
| M&Ms | Expert | 320 (26,846) | 281 (4,815) | – | |
| M&Ms-2 | Expert | 200 (16,449) | 200 (3,841) | 160 | |
| CMR-MULTI cine | Expert | 105 (10,093) | 95 (1,459) | – | |
| MyoPS-related bSSFP cine | Auto. + QC | – | 64 (994) | – | |
| Task | Question answer | Domains | QA |
|---|---|---|---|
| view | imaging view and sequence “Short-axis, cine (bSSFP).” | SAX, LAX, LGE | 7,005 |
| phase | two shuffled frames of one slice which frame is ED and which is ES | SAX, LAX | 9,978 |
| detect | enumerate all structures name and box for each | SAX, LAX | 11,738 |
| bbox | named structure | SAX, LAX | 33,024 |
| point | coordinate structure name, or background | SAX, LAX, LGE | 35,796 |
| highlight | region highlighted in a random colour structure name | SAX, LAX, LGE | 15,038 |
| Domain | Task | QA pairs | Answer counts |
| SAX | Hypertrophy | 4,733 | Absent / present: 4,243 / 490 |
| Regional hypertrophy | 4,733 | Unaffected / affected: 4,243 / 490 | |
| LV size | 3,985 | 2,963 / 412 / 304 / 306 | |
| EF | 3,971 | 2,291 / 732 / 418 / 530 | |
| RV size | 1,221 | Normal / dilated: 994 / 227 | |
| GRS surrogate | 3,713 | Normal / reduced: 2,939 / 774 |
| A. Implemented criteria and reference scope | |||
|---|---|---|---|
| Task | Rule-based reference | Report-based reference | Difference |
| Hypertrophy | Any slice AHA wall thickness mm; reviewed basal/apical positives retained. | Septal or posterior wall thickness mm. | Cut-off gap: 2 mm; slice-wide vs. two report regions. |
| LV size | Product LV EDVi: normal ; mild ; moderate ; severe . | Report LV EDVi above its recorded upper limit: 62 (female) or 75 (male); binary dilation. | Normal-limit gap: 43/30 mL/m 2 . No matched report four-grade scale. |
| RV size | Product RV EDVi mL/m 2 ; if BSA is absent, RV EDV mL. | Explicit normal/enlarged RV description in the report conclusion. | Quantitative rule vs. qualitative finding; not numerically comparable. |
| EF | Product EF: normal ; mild ; moderate ; severe . | Report EF value mapped using the same 50/40/30% bands. | Cut-off gap: 0 percentage points; different measurement sources. |
| GRS | Mean mask-derived systolic wall thickening: reduced ; normal ; excluded. | Any report-mapped middle-segment WMS indicates abnormal motion. | Thickening vs. WMS proxy; not equivalent strain references. |
| Domain | Clinical task | Anatomical prior |
| SAX | Hypertrophy | MYO |
| SAX | Regional hypertrophy | MYO |
| SAX | LV size | LV |
| SAX | EF | LV |
| SAX | RV size | RV |
| SAX | Radial motion (GRS) | MYO |
| Cohort | View | Reference | Task | ACC | BA | Macro- | |
|---|---|---|---|---|---|---|---|
| ACDC-50 | SAX | Internal | LV size | 171 | 78.4 | 63.9 | 62.1 |
| ACDC-50 | SAX | Internal | EF | 171 | 79.5 | 59.3 | 53.4 |
| M&Ms-2 | LAX | Internal | EF | 160 | 56.9 | 53.5 | 51.3 |
| M&Ms-2 | LAX | Internal | EDV | 160 | 75.0 | 71.5 | 62.6 |
| In-house B | SAX | Rule-based | LV size | 1,783 | 70.1 | 41.4 | 31.6 |
| In-house B | SAX | Rule-based | EF | 1,795 | 52.4 | 51.6 | 44.4 |
| Task | ACC | Sens. | Spec. | PPV | BA | Macro- | |
|---|---|---|---|---|---|---|---|
| ACDC-50 (SAX) | |||||||
| Hypertrophy | 457 | 93.4 | 78.0 | 95.3 | 67.2 | 86.7 | 84.3 |
| LV size | 171 | 89.5 | 90.9 | 88.8 | 79.4 | 89.9 | 88.4 |
| RV size | 170 | 91.8 | 75.6 | 97.6 | 91.9 | 86.6 | 88.8 |
| EF | 171 | 90.6 | 98.5 | 85.7 | 81.2 | 92.1 | 90.4 |
| GRS | 160 | 93.8 | 89.8 | 95.5 | 89.8 | 92.6 | 92.6 |
| Task | ACC | Sens. | Spec. | PPV | BA | Macro- | |
|---|---|---|---|---|---|---|---|
| Rule-based | |||||||
| Hypertrophy | 1,945 | 95.6 | 74.9 | 99.3 | 95.3 | 87.1 | 90.7 |
| LV size | 1,783 | 76.1 | 91.0 | 74.0 | 33.2 | 82.5 | 66.6 |
| RV size | 1,795 | 94.9 | 28.6 | 96.5 | 16.4 | 62.5 | 59.1 |
| EF | 1,795 | 66.5 | 92.6 | 54.4 | 48.5 | 73.5 | 66.3 |
| GRS | 1,708 | 95.1 | 77.7 | 96.9 | 71.8 | 87.3 | 86.0 |
| Cohort | Reference | Task | Prec. | Rec. | Micro- | Exact | Jaccard | |
|---|---|---|---|---|---|---|---|---|
| ACDC-50 | Internal | Hypertrophy | 457 | 65.8 | 58.3 | 61.8 | 88.2 | 91.3 |
| ACDC-50 | Internal | Wall motion | 171 | 51.1 | 61.5 | 55.8 | 57.9 | 71.1 |
| In-house B | Rule-based | Hypertrophy | 1,831 | 71.6 | 44.8 | 55.1 | 91.2 | 93.3 |
| In-house B | Rule-based | Wall motion | 1,795 | 33.9 | 40.1 | 36.7 | 76.7 | 80.2 |
| In-house B | Report-based | Hypertrophy | 1,822 | 94.9 | 18.5 | 30.9 | 74.8 | 78.0 |
| In-house B | Report-based | Wall motion | 1,795 | 69.4 | 22.9 | 34.5 | 69.4 | 74.6 |